Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H18N6O |
Molecular Weight | 382.4179 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=NN=C(N1C2=CC=CC3=NON=C23)C4=CC=C(N=C4)C5=CC=CC=C5
InChI
InChIKey=FQGLDGKVKDPVLO-UHFFFAOYSA-N
InChI=1S/C22H18N6O/c1-14(2)21-24-25-22(28(21)19-10-6-9-18-20(19)27-29-26-18)16-11-12-17(23-13-16)15-7-4-3-5-8-15/h3-14H,1-2H3
Molecular Formula | C22H18N6O |
Molecular Weight | 382.4179 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22542656
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22542656
ASP-2535 is a glycine transporter-1 (GlyT1) inhibitor which was developed by Astellas Pharma for the treatment of Schizophrenia and Alzheimer's disease. Although ASP-2535 was shown to improve cognitive impairment in animal models, it is no longer in the company pipeline.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2337 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22542656 |
92.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. | 2012 Jun 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22542656
Rats were given ASP-2535 at a dose of 0.1-3 mg/kg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:40:29 GMT 2023
by
admin
on
Sat Dec 16 11:40:29 GMT 2023
|
Record UNII |
6627LI8F9K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9800113
Created by
admin on Sat Dec 16 11:40:29 GMT 2023 , Edited by admin on Sat Dec 16 11:40:29 GMT 2023
|
PRIMARY | |||
|
6627LI8F9K
Created by
admin on Sat Dec 16 11:40:29 GMT 2023 , Edited by admin on Sat Dec 16 11:40:29 GMT 2023
|
PRIMARY | |||
|
374886-51-8
Created by
admin on Sat Dec 16 11:40:29 GMT 2023 , Edited by admin on Sat Dec 16 11:40:29 GMT 2023
|
PRIMARY | |||
|
ASP-2535
Created by
admin on Sat Dec 16 11:40:29 GMT 2023 , Edited by admin on Sat Dec 16 11:40:29 GMT 2023
|
PRIMARY | ASP 2535: Cat. No. 5308Biological Activity: Potent and selective GlyT1 inhibitor (IC50 = 92 nM). Exhibits 50-fold selectivity over GlyT2. Attenuates MK 801-induced working memory deficits and PCP-induced visual learning deficits in mice. Orally available and brain penetrant. | ||
|
300000042369
Created by
admin on Sat Dec 16 11:40:29 GMT 2023 , Edited by admin on Sat Dec 16 11:40:29 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Astellas Pharma; Class: Antidementia, Antipsychotic; Highest Development Phases: Discontinued for Alzheimer's disease, Schizophrenia; Most Recent Events: 29 May 2009 Discontinued - Phase-I for Schizophrenia in Japan (PO), 29 May 2009 Discontinued - Phase-I for Alzheimer's disease in Japan (PO), 29 Aug 2008 Phase-I clinical trials in Schizophrenia in Japan (PO)
|